- Home
- FJDI vs TARA Comparison
FJDI vs TARA Comparison
Compare FJDI & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FJDI | TARA |
|---|---|---|
| Founded | 2025 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.4M | 159.6M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FJDI | TARA |
|---|---|---|
| Price | $9.90 | $2.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $25.71 |
| AVG Volume (30 Days) | 69.7K | ★ 1.2M |
| Earning Date | N/A | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.84 | $2.30 |
| 52 Week High | $9.90 | $7.82 |
Technical Indicators
Market Signals| Indicator | FJDI | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 71.20 | 32.40 |
| Support Level | $9.85 | N/A |
| Resistance Level | N/A | $2.83 |
| Average True Range (ATR) | 0.02 | 0.16 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 100.00 | 29.91 |
Price Performance
Historical ComparisonAbout FJDI ARC Group Securities Acquisition I Class A Ordinary Shares
ARC Group Securities Acquisition I is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.